Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dorsomorphin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 11/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 10/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 5/20 | 0.98 |
| ▸ | SRC known ✓ | P12931 | 5/20 | 0.98 |
| ▸ | ACVR1 known ✓ | Q04771 | 5/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 6/20 | 0.80 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.80 |
| ▸ | BMP4 | P12644 | 8/20 | 0.98 |
| ▸ | PRKAB2 | O43741 | 7/20 | 0.98 |
| ▸ | PRKAG1 | P54619 | 7/20 | 0.98 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.98 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.98 |
| ▸ | PRKAG3 | Q9UGI9 | 7/20 | 0.98 |
| ▸ | PRKAG2 | Q9UGJ0 | 7/20 | 0.98 |
| ▸ | PRKAB1 | Q9Y478 | 7/20 | 0.98 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.98 |
| ▸ | RPS6KA1 | Q15418 | 5/20 | 0.98 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.98 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.98 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dorsomorphin SCHEMBL2119244 | 1.00 | KDR (0.98) | KDRFLT1BMP4PRKAB2PRKAG1 | |
| Dorsomorphin SCHEMBL463155 | 0.99 | KDR (1.00) | KDRFLT1BMP4PRKAB2PRKAG1 | |
| Dorsomorphin SCHEMBL26968137 | 0.96 | KDR (0.94) | KDRFLT1BMP4PRKAB2PRKAG1 | |
| SCHEMBL2059672 | 0.90 | BMP4 (1.00) | KDRFLT1BMP4PRKAB2PRKAG1 | |
| SCHEMBL11953875 | 0.90 | KDR (0.83) | KDRFLT1BMP4PRKAB2PRKAG1 | |
| SCHEMBL2059673 | 0.89 | PRKAB1 (1.00) | KDRFLT1BMP4PRKAB2PRKAG1 | |
| SCHEMBL31087251 | 0.89 | KDR (0.81) | KDRFLT1BMP4PRKAB2PRKAG1 | |
| SCHEMBL13126023 | 0.89 | FLT1 (0.81) | KDRFLT1BMP4PRKAB2PRKAG1 | |
| SCHEMBL13126025 | 0.89 | KDR (0.81) | KDRFLT1BMP4PRKAB2PRKAG1 | |
| SCHEMBL13126029 | 0.89 | FLT1 (0.81) | KDRFLT1BMP4PRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039798-B1 | SUSPENSION AND CLUSTERING OF HUMAN PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4691479-A2 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240417692-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS | JANSSEN BIOTECH, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-11981929-B2 | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells | JANSSEN BIOTECH, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| CN-117821369-A | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells | 詹森生物科技公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4219683-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS | Janssen Biotech, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4194548-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-2938723-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS | JANSSEN BIOTECH INC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3472303-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4039798-A1 | SUSPENSION AND CLUSTERING OF HUMAN PLURIPOTENT CELLS | Janssen Biotech, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3954759-A1 | USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLS | Janssen Biotech, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3234109-A1 | SUSPENSION CULTURING OF PLURIPOTENT STEM CELLS | Janssen Biotech, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160215268-A1 | Suspension Culturing of Pluripotent Stem Cells | JANSSEN BIOTECH, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2016100035-A1 | SUSPENSION CULTURING OF PLURIPOTENT STEM CELLS | JANSSEN BIOTECH, INC. (US) | 2016-06-23 | — | — | WO | disclosed |